Gavi Backs Merck & Co's Ebola Vaccine Candidate
This article was originally published in Scrip
Executive Summary
Gavi, the global vaccine alliance, has promised Merck & Co. Inc. that it has a customer for its Ebola vaccine candidate rVSV?G-ZEBOV-GP, the only vaccine with Phase III data for the deadly viral infection, through the signing of an 'advance purchase commitment'.